WIN Consortium
“Published in Nature Medicine, results of WINTHER, the first study pioneered by the WIN Consortium. The WINTHER study was one of the last projects of our late Chairman Emeritus Dr John Mendelsohn.” WIN Consortium

WINning together

WIN was formed on the premise that we can accomplish more together than each organization can achieve working alone. We aim to improve cancer patients’ survival and quality of life. View WIN's history and unique attributes:

WIN represents a global collaboration of cancer centers, life science and biotech organizations, pharmaceutical and technology companies and not-for-profit organizations.
The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine was initiated in 2010 with leadership from leading cancer centers worldwide. WIN is a non-profit, non-governmental organization headquartered in Paris.

WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.

WIN now includes 34 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, and the Middle East.

Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
WIN is comprised of organizations representing all stakeholders in personalized cancer medicine.
WIN enables cross-sector collaborations designed to accelerate the speed and efficacy with which breakthroughs in personalized cancer medicine can be realized and brought to patients worldwide.

Our members include leading academic, pharmaceutical, life science, not-for-profit, health, patient advocacy and IT organizations.
Our members include 26 leading academic centers representing 19 countries and four continents, enabling coordinated studies with a global patient population.
The response to a genetically-targeted therapy can vary due to differences in ethnicity and environment. WIN's global studies are designed to identify and account for this variability, enhancing the speed and efficacy with which novel discoveries can be made and brought to patients around the world.

WIN prioritizes cross-sector interaction designed to enhance learning across and between continents and healthcare sectors.
WIN Symposia, held annually, brings together hundreds of leaders representing all stakeholders from around the world in a forum designed to promote the exchange of ideas and information.

Clinical trials and projects

WIN members collaboratively design and carry out global studies designed to achieve breakthroughs for patients worldwide. Our distinguished Scientific Advisory Board oversees WIN studies. Current trials include:

SPRING 01 (Survival Prolongation by Rationale Innovative Genomics) proof of concept trial is the first trial exploring the tri-therapy strategy in first line of advanced/metastatic non-small cell lung cancer (NSCLC), following the historical success of this approach in AIDS and tuberculosis for which only tri-therapy demonstrated long term efficacy.
The WIN SPRING trial will be conducted in the USA, France, Spain, Luxembourg and Israel in the following cancer centers: University of California - San Diego's Moores Cancer Center, Avera Cancer Institute (Sioux Falls, Arizona), Institut Curie (Paris), Centre Léon Bérard (Lyon), Hôpital Paris Saint-Joseph (Paris), Vall d'Hebron Institute of Oncology (Barcelona), Centre Hospitalier de Luxembourg (Luxembourg), and Chaim Sheba Medical Center (Israel).

The trial is sponsored by the WIN Consortium and funded by ARC Fondation for cancer research (France). The drugs are donated by Pfizer Inc.
Published in Nature Medicine, results of WINTHER, the first study pioneered by the WIN Consortium.
Published in Nature Medicine, results of WINTHER, the first study pioneered by the WIN Consortium.

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial - shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone.

WIN is currently planning innovative global clinical trials that represent the next generation of studies focused on lung cancer.
European funded trials WINTHER EU FP7 funded and CHEMORES EU FP6 funded established foundations for WIN future global strategy for lung cancer currently under development.

The concept underlying the new strategy is developed in the following publications:
WIN provides a legal and fundraising framework that enables collective fundraising while protecting its members' intellectual property.
The WIN platform enables multiple organizations from different sectors to productively collaborate while providing for the protection of intellectual property. Each project or clinical trial has its own specific contract or funding mechanism.

People leadership

WIN leaders are selected for their contributions and commitment to making effective, personalized cancer medicine a reality for patients around the world. They guide WIN's strategic, operational, and scientific direction.

Richard L. Schilsky Photo
Richard L. Schilsky

Principal Investigator, TAPUR Study, American Society of Clinical Oncology (ASCO); past ASCO Executive Vice President and Chief Medical Officer (2013-2021)

Josep Tabernero Photo
Vice Chairman, WIN Consortium; Chair, WIN Scientific Advisory Board
Josep Tabernero

Head, Medical Oncology Department, Vall d'Hebron University Hospital (HUVH); Director, Vall d'Hebron Institute of Oncology, VHIO (Spain); Past ESMO President (2019)

Razelle Kurzrock Photo
Chief Medical Officer; Chair, Clinical Trials Committee
Razelle Kurzrock

Associate Director, Clinical Science, Director, Center for Personalized Cancer Therapy, Director, Rare Tumor Clinic, University of California San Diego Moores Cancer Center (USA)

Vladimir Lazar Photo
Chief Scientific and Operating Officer
Vladimir Lazar

Chief Scientific and Operating Officer, WIN Consortium

Our members

WIN members include 34 leading organizations representing all stakeholders in personalized cancer medicine covering 19 countries and 4 continents. Our shared vision is delivering the promise of effective, personalized cancer medicine to patients worldwide.

WIN Symposia

WIN Symposia, held annually, gathers leaders representing a breadth of stakeholders from around the world to learn, share, and collaborate. Visit for registration and additional information.

WIN 2021 Symposium logotype

WIN 2021 Symposium

March 21, 2021 - March 22, 2021

We wish to inform you that, due to the COVID-19 global pandemic, the face-to-face WIN symposium scheduled for March 21-22, 2021 in Barcelona, could no longer be maintained due to the travel restrictions.

We are looking to reschedule the WIN symposium depending on the evolution of the pandemic and will update this website on all new developments.

WIN 2019 Symposium logotype

WIN 2019 Symposium

June 23, 2019 - June 24, 2019

The 11th edition of the WIN Symposia ‘WINnovation and Global Deployment of Precision Oncology’ took place in Paris, France on 23-24 June 2019.

Highlights and further information on the event, WIN 2019 can be found on our dedicated website at

WIN 2018 Symposium logotype

WIN 2018 Symposium

June 25, 2018 - June 26, 2018

The 10th year Anniversary edition of the WIN Symposia took place at the WIN Symposium 2018 in Paris, France on 25-26 June 2018.
The WIN Symposium Organizing Committee had chosen “Global Implementation of Precision Oncology: WINning the War against Cancer” as the theme for this celebratory event.

What people are saying

What people are saying
"WIN is an unique, global, translational clinical research organization with a bold vision to bring cutting edge science and technology to the cure of cancer worldwide. It is a privilege to help guide the organization as Chairman." Richard L. Schilsky, WIN Chairman
What people are saying
"Achieving much needed major clinical breakthroughs in cancer treatment requires bold thinking and action, a can do attitude and winning spirit, and close collaboration of stakeholders and contributors with diverse background and expertise. All this is epitomized by WIN." Vladimir Lazar, Chief Scientific and Operating Officer

A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy
Cancer Research Journal
American Association for Cancer Research (AACR)


Cancer scientists and clinicians are mourning the death of one of the most accomplished members of their community: Dr. John Mendelsohn. He was a pioneer in targeted cancer therapy and was instrumental for the discovery and deployment of the first antagonist epidermal growth factor receptor (EGFR) therapeutic antibodies, broadening the concept of targeted EGFR therapy to encompass other receptor tyrosine kinases, such as HER2, and developing blocking antibody-combination therapy with chemotherapies or radiotherapy. Dr. Mendelsohn, who died on January 7, 2019, always led by the strength of his accomplishments and the humility of his character. Above all, he was a well-revered mentor and clinician, who extended compassion and the gift of his time to patients, colleagues, and mentees alike. In tribute to Dr. Mendelsohn, Cancer Research has invited his former mentees and colleagues who were associated with Dr. Mendelsohn for over three decades to reflect on the broad impact of his work. Here, we discuss Dr. Mendelsohn's illustrious career at three elite academic cancer institutions and hospitals in the United States, his acumen to build, grow, and uplift institutions, and train a generation of medical oncologists, physician scientists, and cancer biologists. His profound legacy on targeted therapy and cancer research and treatment continue to prolong and save the lives of cancer patients globally.

Rakesh Kumar, Marc Van de Vijver, Giampaolo Tortora, Fortunato Ciardiello, Tzipora Goldkorn, Wilson H. Miller Jr and Larry Norton

DOI: 10.1158/0008-5472.CAN-19-0989 Published September 2019
La Fondation ARC pour la recherche sur le cancer poursuit son engagement dans le développement de la médecine de précision et salue les résultats majeurs de l’essai WINTHER
Communiqué DE PRESSE
Villejuif, le 8 juillet 2019

La Fondation ARC pour la recherche sur le cancer poursuit son engagement dans le développement de la médecine de précision et salue les résultats majeurs de l’essai WINTHER

La Fondation ARC pour la recherche sur le cancer est membre et partenaire stratégique du consortium international WIN (Worldwide Innovative Network in personalized medicine) à l’origine de l’étude WINTHER dont les résultats ont été publiés dans la revue Nature Medicine1.

L’objectif de WINTHER était d’offrir un traitement de précision à des patients atteints de cancers à tumeurs solides à partir d’une double approche : analyse de l’ADN tumoral puis comparaison des niveaux d’expression des gènes, ARN, entre tissus sain et tumoral pour les patients chez qui le seul profilage ADN de la tumeur ne permettait pas d’identifier d’anomalies moléculaires actionnables. Cette double approche a permis d’accroître la part des patients pouvant bénéficier d’une thérapie ciblée et signe une avancée très innovante.

L’étude WINTHER s’inscrit par sa thématique - la médecine de précision - et par sa dimension internationale, au cœur des priorités scientifiques de la Fondation ARC qui l’a soutenue à hauteur de 2 millions d’euros. Comme le souligne Nancy Abou-Zeid, Directrice scientifique de la Fondation ARC « l’un des enjeux majeurs de la prise en charge des cancers est la caractérisation fine de la tumeur de chaque patient afin de pouvoir proposer à chacun la thérapie la plus pertinente. L’essai WINTHER a montré que la caractérisation approfondie incluant l’ARN permettait de proposer un traitement personnalisé à un plus grand nombre de patients. C’est une nouvelle avancée dans la médecine de précision en oncologie qui nous encourage à renforcer notre action dans cette direction et au niveau international en soutenant également l’essai SPRING qui évalue une trithérapie ciblée contre les cancers du poumon avancés.

Mené entre avril 2013 et décembre 2015 au Canada, aux États-Unis, en Espagne, en France et en Israël, l’essai WINTHER a porté sur 303 patients atteints de cancers avancés de divers types (poumon, tête et cou, côlon…) et en échec de traitement. Ces patients avaient donné leur accord pour la réalisation d’une double biopsie (tissu sain/tissu tumoral). Les patients chez qui l’analyse de l’ADN tumoral a conduit à l’identification d’anomalies moléculaires actionnables ont été orientés vers une thérapie ciblée correspondant au profil de leur tumeur. Pour les patients chez qui l’analyse de l’ADN tumoral n’a pas été concluante, il a été procédé à la comparaison de l’ARN du tissu sain et du tissu tumoral. La tumeur a pu ainsi être mieux caractérisée. Un algorithme breveté, outil d’aide à la décision mis au point par le consortium WIN dans le cadre de ce projet, a analysé les différences d’expression génique entre la tumeur et le tissu normal, aidant les médecins à prioriser leurs traitements.

Cette stratégie a fait la preuve de sa faisabilité et de son efficacité puisque ce sont au total 107 patients qui ont pu bénéficier d’une thérapie ciblée, soit 35 % des patients inclus, versus 5 à 25 % dans les études de médecine de précision reposant uniquement sur l’analyse de l’ADN tumoral. Plus du quart de ces patients traités a eu un taux de réponse ou de stabilisation de la maladie supérieur à 6 mois, avec un différentiel de 9 % au profit des patients ayant bénéficié du profilage de l’ARN. Grâce à cette prise en charge une amélioration de la survie a été observée de façon claire pour certains des patients, avec un gain médian de plus de 20 mois de survie globale (25,8 versus 4,5 mois).

Comme cela a été souligné lors du Symposium organisé par le Consortium WIN, les 23 et 24 juin à Paris, ce résultat ouvre des perspectives majeures et la possibilité d’explorer de nouvelles pistes thérapeutiques : « les résultats de l’essai WHINTER nous ont permis de lancer en 2017 l’essai SPRING (Survival Prolongation by INnovative Genomics), 1er essai mondial de médecine de précision évaluant les bénéfices d’une trithérapie dans le traitement de première ligne du cancer du poumon non à petites cellules avancé ou métastasique. La phase 1, visant à établir le dosage optimal du traitement, est en passe de se conclure avec des résultats déjà encourageants. La phase 2 de l’étude explorera aussi l’utilité clinique de l’algorithme Simplified Interventional Mapping System (SIMS) dans le but de développer un outil prédictif capable d’accompagner la prescription de la trithérapie. L’apport de la Fondation ARC dans l’élaboration de ce projet mené par notre Consortium a été essentiel. Nous sommes fiers que des initiatives françaises comme WINTHER et SPRING puissent ouvrir de nouvelles perspectives pour l’oncologie de précision mais aussi rayonner à l’international. » indique le Consortium WIN.

L’engagement de la Fondation ARC pour la médecine de précision

La Fondation ARC est déterminée à faire de la médecine de précision une réalité pour un grand nombre de patients. Elle soutient des essais cliniques majeurs dans ce domaine (SAFIR Sein, SAFIR poumon, Programme AcSé, MAPPYACTS...). Acteur majeur de la recherche sur le cancer, la Fondation ARC est membre du consortium international WIN depuis juin 2014. Dans ce cadre, elle apporte un soutien de de 2,8 millions d’euros aux études WINTHER et SPRING. Depuis 2011, la Fondation ARC a permis le lancement de 27 essais cliniques de médecine de précision pour un investissement total de près de 18 millions d’euros.

Pour en savoir plus sur la Fondation ARC pour la recherche sur le cancer :
Pour en savoir plus sur le Consortium WIN :

Fondation ARC pour la recherche sur le cancer 01 45 59 59 48 / 06 45 10 52 75

Céline KERUZORE 06 03 92 15 49

1. Rodon, J. et al ; Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial ; Nature Medicine ; 22 avril 2019
WINTHER Trial Highlights Challenges, Potential of Transcriptomics for Precision Oncology
Apr 22, 2019 Turna Ray
NEW YORK (GenomeWeb) – A newly published study has demonstrated the potential of using transcriptomics to help get cancer patients on treatments they're most likely to benefit from.

The study, called WINTHER, appears today in Nature Medicine and included RNA expression analysis in addition to genetic sequencing to match cancer patients to drugs. Despite demonstrating the promise of the approach, the study did not reach its primary endpoint as it had to deal with the same challenges that have plagued other precision oncology trials.

This is the first trial to match patients with solid tumors to treatments based on transcriptomics, noted Vladimir Lazar, an investigator on WINTHER and chief scientific and operating officer of the WIN Consortium, the body organizing the study. While the trial may not have reached its prespecified endpoint, "the lessons in this trial and results are very important," Lazar said, highlighting a post-hoc analysis that demonstrated the importance of defining the biology driving the tumor and interrogating that biology to "match" patients to treatments.

The study, led by Razelle Kurzrock from the University of California, San Diego Moores Cancer Center, involved 107 evaluable patients with a variety of cancers enrolled at four centers in Spain, Israel, France, and Canada. Of these patients, 69 individuals received treatments based on results following genetic sequencing using Foundation Medicine's FoundationOne test.

In most precision oncology studies, if patients don't match to targeted treatments based on genetic abnormalities, then they don't have any other options. However, in this study, there were 38 such patients who didn't have DNA alterations, but then received microarray-based RNA expression analysis of tumor and normal tissues and received treatments based on that information.

At the time WINTHER was designed "nobody felt that it was reasonable or ethical to start matching by RNA if the patients had a good DNA match," Kurzrock explained. "However — and here is the important thing — if there was no DNA match then we had an additional option."

Researchers evaluated outcomes by using each patient as his or her own control by comparing their progression-free survival in the present trial (PFS2) against the progression-free survival they experienced on the treatment they received prior to entering the trial (PFS1). Because these were heavily pretreated patients, the expectation would be that they would do worse with every subsequent therapy.

WINTHER investigators hoped to show a degree of improvement in patient outcomes in the trial based on matched therapy, and prespecified a PFS2 to PFS1 ratio of greater than 1.5 in 50 percent of patients in the DNA sequencing arm and in 40 percent of patients in the RNA expression analysis arm. The study failed to meet this prespecified endpoint, however, with 20 percent of patients in the DNA sequencing arm and 26 percent of patients in the RNA expression analysis arm exceeding that ratio.

The field of precision oncology, though relatively new, can now boast a number of advances with the recent approval of larotrectinib (Vitrakvi) for patients with NTRK gene fusions, and even a growing list of next-generation treatment options for when patients develop resistance to first generation targeted drugs, as in the case of EGFR inhibitors. "Even though there are many successes in precision oncology ... there are also limitations with some studies showing that many patients don't have durable responses," Kurzrock said. "Then, the question is, why is it that occurs?"

WINTHER, which had aimed to enroll 60 patients in the DNA sequencing arm and 140 patients in the RNA expression analysis arm, faced a number of challenges that may have impacted the results. In fact, the opposite happened, partly due to regulatory delays in the US. Additionally, the prespecified endpoint of PFS2/PFS1 greater than 1.5 was too ambitious, researchers acknowledged during a presentation last year at the American Society of Clinical Oncology's annual meeting.

According to Lazar, a PFS2/PFS1 ratio of greater than 1.3 is accepted in the field and would have pushed the proportion that met the prespecified endpoint in the overall trial from 22 percent to 25 percent. In all 107 patients, 11 percent experienced a complete or partial response, 15 percent had stable disease for six months or longer, and median overall survival was 5.9 months.

In a blinded post-hoc analysis, researchers developed a DNA and RNA matching score and assessed whether patients who received drugs that they were predicted to benefit from based on molecular profiling data fared better than those who didn't. "The matching score ... tries to reflect the degree to which patients were matched," Kurzrock said, noting that the researchers hypothesized that the degree to which a patient is matched to the therapy should make a difference. "And, indeed, that's what the paper shows." Multivariate analysis demonstrated that patients with an ECOG performance status of 0 and a high matching score had the longest overall survival compared to all other subgroups.

"The changes at the DNA level are not all the changes that occur in a cell," Kurzrock explained. "If there is a change at the DNA level but it is not reflected at the RNA level, then you don't have enough information ... The transcriptomics is going to give you more information about the underlying biology that can help you craft an appropriate therapy."

Additionally, tumors are complicated and typically have multiple changes at the DNA and RNA level that are helping them grow and spread. "Therefore, it makes sense that if there are many different drivers of the tumor and you're only addressing a small portion of the drivers then you may not get a great response, because the tumor has alternative mechanisms by which to grow," Kurzrock said.

In the WINTHER trial, patients had very advanced disease, with 26 percent receiving more than five prior treatments. And although around 300 patients consented to partake in the study, many ended up not getting on a treatment because the quality of their biopsies didn't allow for molecular assessments, they dropped out due to poor health status, or died.

"Most precision oncology studies have been plagued by patients enrolling very late ... and [this is] also reflected in WINTHER," Kurzrock said. "Doctors tend to enroll in these studies as a last-ditch [effort] right before hospice, and by that time, the patient is in bad shape and the tumor has evolved tremendously."

Even so, in WINTHER researchers were able to match 35 percent of consented patients to treatments based on DNA sequencing or RNA expression analysis. If the study had relied only on DNA information, the match rate would have been around 23 percent.

Moreover, despite not reaching the primary endpoint in WINTHER, there were suggestions that transcriptomics may better reflect tumor biology in some cases and therefore identify better targeted treatment "matches" than with DNA information. For example, the authors pointed out that the benefit rate in the RNA expression analysis arm was approximately 32 percent compared to 23 percent in the DNA sequencing arm, though this was not statistically significantly higher.

One of the exceptional responders in the study, a patient with refractory gastrointestinal neuroendocrine tumors, did not have any targetable DNA alterations, but transcriptomics revealed she had elevated expression of AKT2 and AKT3. She received the mTOR inhibitor everolimus (Afinitor), and experienced stable disease that's ongoing at nearly three years. The authors wrote this case is particularly notable since when patients are matched to mTOR inhibitors based on DNA alterations they rarely benefit likely due to the existence of other genomic alterations.

The study not only demonstrates the feasibility of incorporating transcriptomics into precision oncology trials, but also highlights the importance of collaboration among researchers across institutions and in different countries. Richard Schilsky, an author on the paper and chief medical officer of ASCO, noted that WINTHER dealt with its share of logistical challenges, for example, ensuring consistent standard operating procedures for tissue collection and handling across multiple centers in different countries and enabling investigators in different time zones to discuss treatment recommendations based on the -omics data.

"Since WINTHER did not test a specific treatment, there were also challenges in patient access to the recommended treatments and collecting consistent patient follow-up data," Schilsky said. In the study, of the 107 who received single or combination treatment with 159 drugs, 115 treatments were given off-label, 22 were prescribed on-label, and 22 were investigational agents.

Despite these challenges, investigators in the WIN Consortium also learned alot from WINTHER, and are now applying those lessons to the SPRING trial, he noted. "The model of global precision medicine trial is absolutely essential to test interventions in molecularly-defined rare patient populations," Schilsky said.
Comprehensive Tumor Profiling Promises New Therapeutic Options for Patients with Advanced Cancer
VILLEJUIF, France--(BUSINESS WIRE)-- Published in Nature Medicine* today, results of WINTHER, the first study pioneered by the WIN Consortium** - - Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial - shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone.

The WINTHER trial***, NCT01856296, led by investigators from Vall d’Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave Roussy (France) (Jean-Charles Soria), Centre Léon Bérard (France) (Pierre Saintigny), Segal Cancer Centre, McGill University (Canada) (Wilson H. Miller), UT MD Anderson Cancer Center (USA) (Jordi Rodon and Apostolia-Maria Tsimberidou) and University of California San Diego, Moores Cancer Center (USA) (Razelle Kurzrock), aimed to expand precision oncology to patients with advanced solid tumors that progressed after treatment with standard therapies.

For the first time in the clinic, the WINTHER trial applied transcriptomics (RNA expression testing) to tailor precision medicine in oncology to a greater number of patients based on the increased expression of RNA in tumors compared to normal tissues.

303 patients were enrolled in WINTHER; 107 of whom were ultimately treated according to recommendations made by a committee of cancer experts spanning five countries. These patients had been heavily pretreated, with one quarter having received five or more prior lines of therapy. Of the 107 patients treated, 69 received treatment based on DNA mutation profiling, and 38 based on RNA profiling. Overall, the WINTHER trial succeeded in matching personalized therapy to 35% of patients with advanced cancer.

“The strategy employed in WINTHER resulted in a higher proportion of patients treated than in many precision medicine trials. Previous studies have identified potential treatments for between 5% and 25 % of patients based on DNA profiling alone, our findings represent an important step toward delivering on the true promise of precision medicine in oncology,” said Richard L. Schilsky, Chairman WIN Consortium and Chief Medical Officer of ASCO.

In this trial, patients were first evaluated for targetable alterations in cancer driver genes. Those who were not matched to drugs based on DNA alterations received a treatment tailored to the differences in gene expression between patients’ tumors and normal tissues which were assessed using a patented algorithm developed by the WIN Consortium. Comparisons with normal tissues proved essential due to highly variable RNA expression between patients and across normal tissue types. The WINTHER researchers showed that RNA expression can be used to expand personalized therapy options for patients and that normal tissue biopsy is safe and accepted by patients.

Patients who received therapy optimally tailored to their respective DNA alterations, or consistent with the algorithm recommendation for RNA guided treatment, responded better. Patients with a good performance status and a high degree of matching had a significantly longer median overall survival of 25.8 months versus 4.5 months for others. There was also a correlation between degree of matching and progression-free survival independent of the number of prior therapies. "Importantly, our results show that patients treated with a drug or regimen more closely matched to the molecular profile of their tumor, do better," observed Razelle Kurzrock, co-leader of the WINTHER trial and Director of UCSD Moores Center for Personalized Cancer Therapy.

“Assessing RNA is an important adjunct to DNA profiling for determining precision treatments. WINTHER rings in a new era for personalized medicine in oncology,” concluded Josep Tabernero, Vice-Chairman WIN Consortium, Director VHIO and President ESMO.


** About WIN: WIN Consortium is a non-profit organization based in Paris, France. We are a worldwide network assembling cancer stakeholders from four continents to develop cutting edge concepts and clinical trials that improve survival for cancer patients. WIN members include 28 outstanding cancer centers plus 8 additional leading pharmaceutical, technology companies and patient advocacy organizations representing stakeholders in precision cancer medicine,

*** WINTHER received funding from the European Union Seventh Framework Program (FP7/2007-2013 under grant agreement n°306125), ARC Foundation for cancer research (France), Pfizer Oncology, Lilly France SAS, and Novartis Pharmaceuticals Corporation.

Vladimir Lazar